Jerry Nick is a Respiratory physician affiliated with National Jewish Health. OpenAlex indexes 215 publications with 9,982 citations (h-index 51); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Jackson St
Denver, CO 802062761
Telephone
303-388-4461Registry record last updated 26 Apr 2013.
Clinical trials
- Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Sponsor: National Jewish Health
- Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY
Sponsor: National Jewish Health
- Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening
Sponsor: Jerry A. Nick, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Paratek Pharmaceuticals, Inc.Program year20253 payments
- ABBVIE INC.Program year20252 payments
- Insmed, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
56.1%Other respiratory system products36.9%Trikafta96%Symdeko4%Part D<11 patientsbeta2-Adrenergic Agonist8.7%Albuterol Sulfate Hfa81%Serevent Diskus20%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
22%Antidiarrheal microorganisms13.2%Zenpep55%Creon45%Part D≥12 patientsProton pump inhibitor3.7%Omeprazole55%Pantoprazole Sodium46%Part D<11 patients+ 2 more classes in this area
Anti-infectives
10.1%Macrolide Antimicrobial5.5%Azithromycin100%Part D≥11 patientsFluoroquinolone Antibacterial1.8%Levofloxacin100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1997–2022 per NIH RePORTER. The latest:
- Prospective Longitudinal Assessment of Culture-Independent Molecular Airway Markers of Nontuberculous Mycobacteria
National Jewish Health
FY2022$410,000R01HL146228 - Prospective Longitudinal Assessment of Culture-Independent Molecular Airway Markers of Nontuberculous Mycobacteria
National Jewish Health
FY2021$410,000R01HL146228 - Prospective Longitudinal Assessment of Culture-Independent Molecular Airway Markers of Nontuberculous Mycobacteria
National Jewish Health
FY2020$410,000R01HL146228
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Population Genomics of <i>Mycobacterium abscessus</i> from U.S. Cystic Fibrosis Care Centers
Annals of the American Thoracic Society
2021 - A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis
Journal of Cystic Fibrosis
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Leung, MD
National Jewish Health
James Crapo, MD
National Jewish Health
Barry Make, MD
National Jewish Health
Charles Daley, MD
National Jewish Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”